EP1357873A2 - Therapeutic film forming composition and treatment system therefor - Google Patents
Therapeutic film forming composition and treatment system thereforInfo
- Publication number
- EP1357873A2 EP1357873A2 EP02717290A EP02717290A EP1357873A2 EP 1357873 A2 EP1357873 A2 EP 1357873A2 EP 02717290 A EP02717290 A EP 02717290A EP 02717290 A EP02717290 A EP 02717290A EP 1357873 A2 EP1357873 A2 EP 1357873A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- treatment system
- composition
- weight
- treatment
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 66
- 238000011282 treatment Methods 0.000 title claims abstract description 66
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 25
- 239000000126 substance Substances 0.000 claims abstract description 17
- 201000010099 disease Diseases 0.000 claims abstract description 14
- -1 acetones ethers Chemical class 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 13
- 239000004014 plasticizer Substances 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 229940127089 cytotoxic agent Drugs 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 238000010276 construction Methods 0.000 claims description 7
- 230000002708 enhancing effect Effects 0.000 claims description 7
- 235000019441 ethanol Nutrition 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000004202 carbamide Substances 0.000 claims description 6
- 229920002678 cellulose Chemical class 0.000 claims description 6
- 239000001913 cellulose Chemical class 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000002955 immunomodulating agent Substances 0.000 claims description 6
- 229940121354 immunomodulator Drugs 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 6
- 239000011118 polyvinyl acetate Substances 0.000 claims description 6
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 5
- 229920002554 vinyl polymer Polymers 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 4
- 229940124091 Keratolytic Drugs 0.000 claims description 4
- 229940035674 anesthetics Drugs 0.000 claims description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 4
- 230000002141 anti-parasite Effects 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 229940125715 antihistaminic agent Drugs 0.000 claims description 4
- 239000000739 antihistaminic agent Substances 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 235000006708 antioxidants Nutrition 0.000 claims description 4
- 229940125687 antiparasitic agent Drugs 0.000 claims description 4
- 239000003096 antiparasitic agent Substances 0.000 claims description 4
- 239000003443 antiviral agent Substances 0.000 claims description 4
- 239000003246 corticosteroid Substances 0.000 claims description 4
- 229960001334 corticosteroids Drugs 0.000 claims description 4
- 239000002254 cytotoxic agent Substances 0.000 claims description 4
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 4
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 claims description 4
- 150000002170 ethers Chemical class 0.000 claims description 4
- 239000003193 general anesthetic agent Substances 0.000 claims description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
- 230000001530 keratinolytic effect Effects 0.000 claims description 4
- 239000003410 keratolytic agent Substances 0.000 claims description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 3
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 3
- 229920008347 Cellulose acetate propionate Polymers 0.000 claims description 3
- 241000723346 Cinnamomum camphora Species 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims description 3
- 239000000020 Nitrocellulose Substances 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 3
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 3
- 229960000846 camphor Drugs 0.000 claims description 3
- 229930008380 camphor Natural products 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- 229920002301 cellulose acetate Polymers 0.000 claims description 3
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims description 3
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- 239000001087 glyceryl triacetate Substances 0.000 claims description 3
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 229920001220 nitrocellulos Polymers 0.000 claims description 3
- 125000005498 phthalate group Chemical class 0.000 claims description 3
- 229920002451 polyvinyl alcohol Chemical class 0.000 claims description 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 150000005846 sugar alcohols Polymers 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 239000011269 tar Substances 0.000 claims description 3
- 230000037317 transdermal delivery Effects 0.000 claims description 3
- 229960002622 triacetin Drugs 0.000 claims description 3
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 2
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 claims description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 2
- 229920002498 Beta-glucan Polymers 0.000 claims description 2
- 108010006654 Bleomycin Proteins 0.000 claims description 2
- 229920000181 Ethylene propylene rubber Polymers 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 2
- 229930182566 Gentamicin Natural products 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 239000004743 Polypropylene Substances 0.000 claims description 2
- 239000004098 Tetracycline Substances 0.000 claims description 2
- 229960004150 aciclovir Drugs 0.000 claims description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 229960002537 betamethasone Drugs 0.000 claims description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 2
- 229960001561 bleomycin Drugs 0.000 claims description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
- 229960002227 clindamycin Drugs 0.000 claims description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 claims description 2
- 229960003338 crotamiton Drugs 0.000 claims description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 2
- 229960000520 diphenhydramine Drugs 0.000 claims description 2
- 229960005426 doxepin Drugs 0.000 claims description 2
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims description 2
- 229960003276 erythromycin Drugs 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 230000008020 evaporation Effects 0.000 claims description 2
- 229960002518 gentamicin Drugs 0.000 claims description 2
- 229960000890 hydrocortisone Drugs 0.000 claims description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims description 2
- 229960002751 imiquimod Drugs 0.000 claims description 2
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 claims description 2
- 229960004194 lidocaine Drugs 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 2
- 229960000282 metronidazole Drugs 0.000 claims description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 2
- RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960000490 permethrin Drugs 0.000 claims description 2
- 229920001748 polybutylene Polymers 0.000 claims description 2
- 229920000728 polyester Polymers 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 229920000098 polyolefin Polymers 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims description 2
- 229960001807 prilocaine Drugs 0.000 claims description 2
- 229920005989 resin Polymers 0.000 claims description 2
- 239000011347 resin Substances 0.000 claims description 2
- 229960004889 salicylic acid Drugs 0.000 claims description 2
- 229960002180 tetracycline Drugs 0.000 claims description 2
- 229930101283 tetracycline Natural products 0.000 claims description 2
- 235000019364 tetracycline Nutrition 0.000 claims description 2
- 150000003522 tetracyclines Chemical class 0.000 claims description 2
- 229960001295 tocopherol Drugs 0.000 claims description 2
- 235000010384 tocopherol Nutrition 0.000 claims description 2
- 229930003799 tocopherol Natural products 0.000 claims description 2
- 239000011732 tocopherol Substances 0.000 claims description 2
- 229960005294 triamcinolone Drugs 0.000 claims description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 2
- 150000001253 acrylic acids Chemical class 0.000 claims 2
- 125000004063 butyryl group Chemical class O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 229920001169 thermoplastic Polymers 0.000 claims 2
- 239000004416 thermosoftening plastic Substances 0.000 claims 2
- 150000003613 toluenes Chemical class 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 1
- 239000012790 adhesive layer Substances 0.000 claims 1
- 210000003423 ankle Anatomy 0.000 claims 1
- 230000000843 anti-fungal effect Effects 0.000 claims 1
- 230000002924 anti-infective effect Effects 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 210000000617 arm Anatomy 0.000 claims 1
- 239000013536 elastomeric material Substances 0.000 claims 1
- 210000001513 elbow Anatomy 0.000 claims 1
- 210000003811 finger Anatomy 0.000 claims 1
- 210000002683 foot Anatomy 0.000 claims 1
- 210000002414 leg Anatomy 0.000 claims 1
- 230000013011 mating Effects 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 210000003371 toe Anatomy 0.000 claims 1
- 210000000707 wrist Anatomy 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 abstract description 12
- 208000035475 disorder Diseases 0.000 abstract description 11
- 208000000260 Warts Diseases 0.000 abstract description 7
- 201000010153 skin papilloma Diseases 0.000 abstract description 7
- 208000004554 Leishmaniasis Diseases 0.000 abstract description 3
- 230000035515 penetration Effects 0.000 abstract description 3
- 201000005708 Granuloma Annulare Diseases 0.000 abstract description 2
- 208000000453 Skin Neoplasms Diseases 0.000 abstract description 2
- 210000000282 nail Anatomy 0.000 description 66
- 210000003491 skin Anatomy 0.000 description 27
- 208000026721 nail disease Diseases 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 5
- 239000003961 penetration enhancing agent Substances 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000003570 air Substances 0.000 description 4
- 210000004905 finger nail Anatomy 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000000394 mitotic effect Effects 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 210000004906 toe nail Anatomy 0.000 description 4
- 208000006187 Onycholysis Diseases 0.000 description 3
- 206010041663 Splinter haemorrhages Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000004904 fingernail bed Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001185 psoriatic effect Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 229920002725 thermoplastic elastomer Polymers 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 208000002506 Darier Disease Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 229920003155 Eudragit® RL 100 Polymers 0.000 description 2
- 206010018381 Glomus tumour Diseases 0.000 description 2
- 206010018852 Haematoma Diseases 0.000 description 2
- 208000002078 Ingrown Nails Diseases 0.000 description 2
- 206010028698 Nail dystrophy Diseases 0.000 description 2
- 206010048886 Onychoclasis Diseases 0.000 description 2
- 208000010195 Onychomycosis Diseases 0.000 description 2
- 206010033554 Palmoplantar keratoderma Diseases 0.000 description 2
- 206010037649 Pyogenic granuloma Diseases 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000000806 elastomer Substances 0.000 description 2
- 208000017338 epidermoid cysts Diseases 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 201000004607 keratosis follicularis Diseases 0.000 description 2
- 239000004922 lacquer Substances 0.000 description 2
- 201000010192 nonsyndromic congenital nail disorder 1 Diseases 0.000 description 2
- 201000008743 palmoplantar keratosis Diseases 0.000 description 2
- 206010035116 pityriasis rubra pilaris Diseases 0.000 description 2
- 229940075065 polyvinyl acetate Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011277 treatment modality Methods 0.000 description 2
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 description 1
- 201000004625 Acrodermatitis Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 208000023095 Autosomal dominant epidermolytic ichthyosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000013165 Bowen disease Diseases 0.000 description 1
- 208000019337 Bowen disease of the skin Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010062759 Congenital dyskeratosis Diseases 0.000 description 1
- 206010012426 Dermal cyst Diseases 0.000 description 1
- 208000001154 Dermoid Cyst Diseases 0.000 description 1
- 208000010305 Epidermal Cyst Diseases 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 201000009040 Epidermolytic Hyperkeratosis Diseases 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 208000005917 Exostoses Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000003367 Hypopigmentation Diseases 0.000 description 1
- 206010022013 Ingrowing nail Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 206010023369 Keratosis follicular Diseases 0.000 description 1
- 208000001913 Lamellar ichthyosis Diseases 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 206010066945 Lichen striatus Diseases 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010061304 Nail infection Diseases 0.000 description 1
- 206010058455 Nail pigmentation Diseases 0.000 description 1
- 206010028703 Nail psoriasis Diseases 0.000 description 1
- 206010030336 Onychogryphosis Diseases 0.000 description 1
- 206010049274 Onychomadesis Diseases 0.000 description 1
- 208000005775 Parakeratosis Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 206010037575 Pustular psoriasis Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040865 Skin hyperpigmentation Diseases 0.000 description 1
- 206010040868 Skin hypopigmentation Diseases 0.000 description 1
- 206010041736 Sporotrichosis Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229920002522 Wood fibre Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940008309 acetone / ethanol Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 201000000751 autosomal recessive congenital ichthyosis Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 229910001567 cementite Inorganic materials 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 201000005620 dermis tumor Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000009356 dyskeratosis congenita Diseases 0.000 description 1
- 208000002169 ectodermal dysplasia Diseases 0.000 description 1
- 208000031068 ectodermal dysplasia syndrome Diseases 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 description 1
- 208000033286 epidermolytic ichthyosis Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 206010024428 lichen nitidus Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 208000011856 onychomatricoma Diseases 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000003619 porokeratosis Diseases 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229960001896 pramocaine Drugs 0.000 description 1
- DQKXQSGTHWVTAD-UHFFFAOYSA-N pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940126703 systemic medication Drugs 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 201000005882 tinea unguium Diseases 0.000 description 1
- 229940126702 topical medication Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 206010055031 vascular neoplasm Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000002025 wood fiber Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q3/00—Manicure or pedicure preparations
- A61Q3/02—Nail coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F7/02—Compresses or poultices for effecting heating or cooling
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This invention relates to diseases found in and beneath fingernails, toe-nails and on skin surfaces and, more particularly, to a fully integrated treatment system for delivering drug therapy to diseases affecting nails and skin surfaces.
- the nail is a unique keratinous appendage that is produced by the germinative epithelium of the matrix.
- the construction of a typical nail is similar to the construction of the skin surface in which the basal epidermal cells produce the stratum corneum.
- the nail has a harder keratin than the skin because of the higher concentration of sulfur matrix protein.
- the nail grows continuously without a resting phase by adding new cells from the matrix.
- the epithelial components of the nail unit include the proximal nail fold that is similar to the skin or slightly acanthotic, with a granular layer having active mitotic activity.
- the horny end product is the cuticle.
- the matrix is acanthotic without a granular layer with very inactive mitotic activity.
- the horny end product is the nail plate.
- the nail bed is very flat without a granular layer with very inactive mitotic activity and only a few horny cells added to the underside of the nail plate as it moves distally.
- the hyponychium is acanthotic, with a granular layer having active mitotic activity, with only a few horny cells added to the underside of the nail plate distally, similar to the cuticle.
- Onychomadesis complete onyholysysis or spontaneous nail shedding
- Hapalonychia soft nail
- Onychorrhexis senile, old nail
- Cysts (Epidermal Inclusion/Epidermoid cyst) Onychomatricoma Melanocytic Tumors Glomus Tumor
- Fungal infections skin tophytes, yeast, deep fungus
- Bacterial infections gram positive, gram negative bacteria, etc.
- Viral Infections (herpes simplex, warts, etc.)
- Other Infections (Atypical Mycobacteria, sporotrichosis, leishmanias is etc . )
- the clinical signs of psoriasis of the nails are dependent upon the anatomic sites of the nail unit that is involved.
- the defects vary greatly and include pitting of one or more nails, discoloration, thickening, and onycholysis (separation from the nail bed).
- onycholysis separation from the nail bed.
- the effect of onycholysis can also involve the underlying subungual build-up similar to onychomycoses.
- nail plate dystrophy Other changes commonly found are nail plate dystrophy, Mee's lines (transverse white lines in the nail plate), Muehrcke's lines (transverse white lines due to abnormal vascular pattern in the nail bed visible through the nail plate), splitting of the nail plate, Beau's lines (transverse furrow in the nail plate generally due to intermittent matrix psoriasis), splinter hemorrhage, and subungual hyperkerertosis.
- Another object of the present invention is to provide a highly effective treatment system having the characteristics featured detailed above which also employs a heat gradient to further enhance the delivery of the therapeutic agents.
- Another object of the present invention is to provide a highly effective treatment system having the characteristics featured detailed above which is capable of being easily and effectively employed for treating a wide variety of medical conditions.
- the treatment system of the present invention possesses broad applicability for a wide range of medical conditions.
- the numerous diseases, disorders, and medical problems detailed above are all capable of being treated using the present invention.
- diseases, disorders, and medical conditions including, but not limited to psoriasis, skin cancers, warts, leishmaniasis, mycobacteria, and granuloma annulare can be specifically treated or improved due to the efficacy of the present invention and, when employed, the efficacy of heat penetration in treating these disorders.
- the use of heat produces a positive, synergistic effect on the targeted, controlled delivery of predetermined amounts of drugs, and/or penetration enhancing agents.
- the topical use of the drugs and/or penetration enhancing agents for the treatment of the nail diseases, disorders, and medical conditions and/or skin and subcutaneous surfaces, as fully detailed above, are improved or effectively treated by the use of the present invention.
- the delivery of drugs and/or penetration enhancing agents to the nail, or through the nail to the underlying tissue, for the purpose of achieving a non-oral and/or non-parenteral, systemic, transdermal delivery is effective on its own and is further enhanced by the presence of a controlled heat gradient.
- the treatment system of the present invention is detailed below in association with its application to nails and the underlying tissue associated with nails.
- the present invention has equal applicability to diseases, disorders, and medical problems found on skin surfaces which are unassociated with nails. Consequently, it is to be understood that the present invention and the disclosure provided herein is equally applicable to use on any skin surface. Consequently, the detailed use and application to the nails is provided for exemplary purposes only and, as a result, the present invention is intended to encompass application and use on both nails and skin surfaces.
- One principal component of the present invention is a film forming composition which is specifically formulated for delivering one or more therapeutic substances to the site on which it is applied. While usable on any surface of the human body, the film forming position is particularly usable on nails for treating any desired nail disease.
- the film forming composition of this invention also preferably comprises a film former, a plasticizer, and urea, all of which are in a volatile carrier.
- the film former comprises at least one selected from the group consisting of poly vinyl acetate, mixed polymers of vinyl acetate and acrylic acid, mixed polymers of (meth) acrylic acid and (meth) aery late esters, poly vinyl acetate, poly vinyl butyryl, poly vinyl alcohols, cellulose derivatives such as cellulose acetate phthalate, cellulose acetate butyrate, cellulose acetate propionate, cellulose nitrate, cellulose sulfate, ethylcellulose, and cellulose acetate.
- one preferred film former is ammonio methacrylate copolymer (II) sold under the brand name "Eudragit RL-100" by Rohm Pharma GmbH, Rothstadt, Germany.
- the plasticizer composition comprises as least one selected from the group consisting of triacetin, polyhydric alcohols such as propylene glycol and butylene glycol, castor oil, camphor and phthalates.
- one preferred plasticizer comprises dibutyl phthalate, sold under the brand name "Eastman DBT Plasticizer” by Eastman Chemicals.
- any suitable solvent or volatile carrier may be employed.
- the solvent/volatile carrier preferably comprises one or more selected from the group consisting of alcohols (such as ethanol), ketones (such as acetone), ethers (such as chloroform), aromatic hydrocarbons (such as toluene), esters (such as ethyl acetate), and water.
- the preferred compound or compounds should act as a solvent for the carrier and at an evaporation rate which is slow enough to allow a complete application of the active ingredients to nail or skin surfaces, as well as being fast enough to prevent rub-off of the composition in the event the nail or skin surface comes into contact with another surface.
- the film former namely Eudragit RL-100
- the film former namely Eudragit RL-100
- the other ingredients are added and intermixed therein until completely dissolved.
- the desired therapeutic agents are also added and intermixed therewith to form the desired therapeutic film forming composition for application to the nails or skin.
- the therapeutic substance employed comprises one or more selected from the group consisting of corticosteroids, chemotherapeutic agents, anesthetics, antihistamines, anti- bacterials, anti-parasitics, anti-viral agents, anti-oxidants, tar, anthralines, immunomodulators, keratolytics, and anti-neoplasties.
- corticosteroids chemotherapeutic agents, anesthetics, antihistamines, anti- bacterials, anti-parasitics, anti-viral agents, anti-oxidants, tar, anthralines, immunomodulators, keratolytics, and anti-neoplasties.
- enhancing agents which particularly benefit from the use of this embodiment of the present invention comprise one or more selected from the group consisting of solvents, surfactants, ethers, esters, fatty acid glycerides, urea, oleates, liposomes, retinoids, and occlusive compounds.
- the present invention comprises the use of a therapeutic film forming composition independently in one embodiment, and also comprises the use of a heat delivery member which is employed in combination with the therapeutic film forming composition.
- the therapeutic film forming composition is applied to the nail and/or skin surface.
- the heat delivery member when employing this embodiment, is placed over the nail to provide a continuous heat gradient directly to the affected nail and/or skin surface.
- heat delivery is preferably achieved by employing a heat delivery pad used in combination with a holding member.
- an exothermic pad or heat delivery patch is employed for the heat source.
- Exothermic pads or heat delivery patches have been previously developed and typically comprise a porous film or pad of woven or non-woven material incorporating chemicals which will react exothermically to generate heat in the presence of oxygen. Although any desired chemicals can be employed, exothermic pads or heat delivery patches typically contain moxa or a mixture of iron powder, activated charcoal, wood fibers, water and salt.
- any alternate heat producing pad, product, or construction can be employed.
- the patch/pad Prior to use, the patch/pad is typically sealed within a pouch which is odorless or formed with an inert gas, such as nitrogen. As long as the patch/pad remains in the sealed container until use, no chemical reaction takes place. However, once the pouch is open, the presence of the oxygen in the air causes the chemicals to react and the desired exothermic reaction is produced.
- an inert gas such as nitrogen
- the exothermic pad or heat delivery patch is separately employed by having the user place the pad or patch on the desired site where heat treatment is being sought. If desired, the heat delivery patch or exothermic pad is separately secured to the desired site by adhesive means associated therewith.
- the holding member of the treatment system of the present invention is affixed to the desired location, peripherally surrounding and securely maintaining the heating pad or exothermic patch in the desired location, assisting in regulating and controlling the heat level and air transmission to the exothermic pad or heat delivery patch.
- the desired, controlled heat delivery or heat gradient is realized, enabling a broad range of medical conditions to be effectively treated.
- the use of a heat gradient as provided by this embodiment of the fully integrated treatment system of the present invention is effective, improving and enhancing the penetration of the systemic and topical medications incorporated in the therapeutic film forming composition.
- one embodiment of the treatment system of the present invention incorporates a heat delivery patch or exothermic pad in combination with a holding member which maintains the heat delivery patch or exothermic pad in a precisely desired location where the particular medical problem is manifested or where heat delivery or a heat gradient is desired.
- nail or skin penetration enhancing agents may be integrated into the treatment system of this invention for further enhancement of its efficacy.
- One area in which the use of heat has been widely documented is in the treatment of warts. In this regard, heat treatment for warts is fully disclosed in Dvoretzkv. U.S. Patent 5,053,024.
- the temperature of the nail or skin is elevated and maintained between about 39° to 45 °C , for periods of time ranging between about 1 and 10 hours.
- the heat level to which the nail or skin is exposed is maintained in a small, controlled range, which represents the optimum heat exposure for treating the medical condition and delivering the precisely desired medicines. As a result, optimum performance and treatment is realized.
- the support member is specifically designed for being quickly and easily mountable to a part of the body, such as a finger, in peripheral, surrounding engagement with the nail being treated, and remain in the precisely desired location in cooperating association with the film forming composition and the heat delivery patch or exothermic pad.
- the support member of the present invention is also specifically constructed from material particularly designed for cooperating with a heat delivery patch or exothermic pad to synergistically interact therewith for assuring that the precisely required temperature levels are maintained and optimum oxygen flow is realized for the precisely desired period of time.
- the support member forming a component of the holding system of the present invention may be constructed in a variety of alternate configurations for providing the desired, quicky, easy, secure mounting thereof directly to any finger or toe, or any other portion of the human anatomy where treatment is likely to be needed.
- one embodiment of the holding system of the present invention comprises a continuous, substantially cylindrically shaped tube member.
- One feature of the present invention is the material employed for forming the treatment system of this invention.
- most woven or non-woven materials are capable of being employed for forming the holding member.
- the preferred material comprises an elastomer in its entirety or formed therein, in order to provide flexibility in easily mounting and securing the holding system in place.
- the elastomer is integrally formed as a part of the material, such as a thermoplastic elastomer.
- the preferred thermoplastic material comprises a foamed thermoplastic elastomer selected from the group consisting of polyurethane, polyolefins, polybutylenes, polyethylenes, polyesters, ethylene-propylene rubbers, polypropylenes, silicones, and vinyl based resins.
- a foamed thermoplastic elastomer selected from the group consisting of polyurethane, polyolefins, polybutylenes, polyethylenes, polyesters, ethylene-propylene rubbers, polypropylenes, silicones, and vinyl based resins.
- the temperature delivered directly to the nail or skin surface by the exothermic pad or heat delivery patch is precisely controlled in a narrow range, for a predetermined length of time, due to the insulation provided by the holding system.
- oxygen is circulated continuously through the holding system to provide proper operation of the exothermic pad/patch as well as provide air circulation to the surface of the nail or skin being treated.
- ingredients or compounds recited in the singular are intended to include compatible mixtures of such ingredients whenever the sense permits.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Abstract
By providing a film forming composition incorporationg one or more therapeutic substances for application to nails and/or skin surfaces which can be employed independently or, if desired, in combination with an easily employed holding or support member for delivering heat directly to the application site an easily employed, convenient, consumer-oriented treatment system is achieved for treating nails and/or skin surfaces for a wide variety of medical problems. The treatment system of the present invention possesses broad applicability for a wide range of medical conditions, including the mumerous diseases, disorders, and medical problems, all of which are capable of being treated using the present invention. In particular, diseases, disorders, and medical conditionss which include, but are not limited to, psoriasis, skin cancers, warts, leishmaniasis, mycobacteria, and granuloma annulare can be specifically treated or improved due to the efficacy of the present invention and, when employed, the efficacy of heat penetration in treating these disorders.
Description
THERAPEUTIC FILM FORMING COMPOSITION AND TREATMENT SYSTEM THEREFOR
TECHNICAL FIELD
This invention relates to diseases found in and beneath fingernails, toe-nails and on skin surfaces and, more particularly, to a fully integrated treatment system for delivering drug therapy to diseases affecting nails and skin surfaces.
BACKGROUND ART
Diseases which affect the skin surfaces and/or the fingernails and/or toenails of individuals are extremely common and often create substantial difficulties for the individuals who are effected. As detailed herein, a wide variety of the diseases have been found to afflict individuals in this manner, with no realistically effective remedy being available.
In order to recognize the difficulties encountered in this area, it is important to understand the unique structure of nails. As is well known, the nail is a unique keratinous appendage that is produced by the germinative epithelium of the matrix. The construction of a typical nail is similar to the construction of the skin surface in which the basal epidermal cells produce the stratum corneum. However, the nail has a harder keratin than the skin because of the higher concentration of sulfur matrix protein.
The nail grows continuously without a resting phase by adding new cells from the matrix. The epithelial components of the nail unit include the proximal nail fold that is similar to the skin or slightly acanthotic, with a granular layer having active mitotic activity. The horny end product is the cuticle. The matrix is acanthotic without a granular layer with very inactive mitotic activity. The horny end product is the nail plate. The nail bed is very flat without a granular layer with very inactive mitotic activity and only a few horny cells added to the underside of the nail plate as it moves distally. Finally, the hyponychium is acanthotic, with a granular layer having active mitotic activity, with only a few horny cells added to the underside of the nail plate distally, similar to the cuticle.
A wide variety of problems can be incurred either in the nail itself or below the nail surface in treating nails and diseases of the nail. In order to fully understand the magnitude of this problem, the following tables are provided as representative sample listings of various diseases, disorders, and medical problems that can be experienced and are in need of effective treatment:
TABLE A Dermatological Diseases that Affect the Nail
Psoriasis/pustular psoriasis
Lichen Planus Idiopathic Atrophy of the nail
Lichen Nitidus
Lichen Striatus
Inflammatory Linear Verrucous Epidermal News
Alopecia Areata Twenty-Nail Dystrophy (Trachyonychia)
Eczema with nail involvement
Pornpholyx with nail involvement
Parakeratosis pustalosa
Pemphigus Vulgaris Bullous Pemphigoid
Acquired Epidermolysis Bullosa
Erythema Multiforme with nail involvement
Darier's Disease
Pityriasis Rubra Pilaris Palmoplantar Keratoderma
Bazex Syndryome
TABLE B
Nail Involvement in Systemic Diseases
Onycholysis which is the third most common nail disorder seen in dermatology, after onychomycosis and warts. Chromonychia
Hemorrhagic condition
Onychomadesis (complete onyholysysis or spontaneous nail shedding) Hapalonychia (soft nail) Onychorrhexis (senile, old nail) Trachyonychia
TABLE C
Tumors of the Nails Epidermal Tumors Benign Subungual corn
Wart
Cysts (Epidermal Inclusion/Epidermoid cyst) Onychomatricoma Melanocytic Tumors Glomus Tumor
Myxoid Cyst Pyogenic Granuloma Malignant
Bowen's disease/squamous cell carcinoma Maligant Melonoma
Dermal Tumors Benign
Fibroma
Vascular Tumors Glomus Tumor Pyogenic Granuloma Splinter Hemorrhages Subungeal Tumors
Subungeal exostosis Subungeal Hematomas Pigmented Disorders
Hypo/Hypermelanosis/melanonychia Infections
Fungal infections (dermatophytes, yeast, deep fungus) Bacterial infections (gram positive, gram negative bacteria, etc.) Viral Infections (herpes simplex, warts, etc.) Other Infections (Atypical Mycobacteria, sporotrichosis, leishmanias is etc . )
Mixed Infection (paronichia)
TABLE D Congenital Keratinizing Disorders
Darier- White Disease Pachonichia Congenita
Congenital Onychodysplasia
Epidermolysis bullosa
Twenty-Nail Dystrophy
Pityriasis Rubra Pilaris Lamellar Ichthyosis
Epidermolytic Hyperkeratosis
Porokeratosis
Palmoplantar keratoderma
Periodic Shedding of the the nails Ectodermal Dysplasia Rothmund-Thompson Syndrome Dyskeratosis Congenita Acrodermatitis enteropatica
Goldtz' Syndrome Kid Syndrome
TABLE E
Nail Changes/Disorders Associated with Aging Changes
Discoloration
Contour/Shape
Surface abnormality
Thickness Decreased Linear Growth
Disorders
Brittle Nails
Onychodystrophy - exogenous
Onychauxis Onychoclavus (subungeal corn)
Onychocryptosis (Ingrown nail)
Onychogryphosis
Splinter Hemorrhages
Subungeal Hematoma Nail Infection
One of the areas that has proven to be extremely difficult for individuals to obtain an effective remedy is found in the treatment of psoriasis, particularly
psoriasis associated with fingernails or toenails. It is estimated that there are more than 6.4 million cases of psoriasis in the United States, affecting about 2% to 3% of the general American population. According to the National Psoriasis Foundation, about 200,000 new cases are diagnosed every year, with an annual total outpatient cost of between about $1.6 in $3.2 billion being incurred. Furthermore, it is estimated that 56 million hours of work are lost each year by patients with psoriasis. Psoriasis of the nails is very common and has been found in up to 50% of all patients. The fingernails seem to be affected more often than toenails, which presents an additional problem since patients are more likely to complain about nail changes which are readily visible. As a result, the effects of psoriatic nail disease are both physical and psychological.
The clinical signs of psoriasis of the nails are dependent upon the anatomic sites of the nail unit that is involved. The defects vary greatly and include pitting of one or more nails, discoloration, thickening, and onycholysis (separation from the nail bed). The effect of onycholysis can also involve the underlying subungual build-up similar to onychomycoses. Other changes commonly found are nail plate dystrophy, Mee's lines (transverse white lines in the nail plate), Muehrcke's lines (transverse white lines due to abnormal vascular pattern in the nail bed visible through the nail plate), splitting of the nail plate, Beau's lines (transverse furrow in the nail plate generally due to intermittent matrix psoriasis), splinter hemorrhage, and subungual hyperkerertosis.
The objective of treating psoriatic nail disease is to improve the physical and physchosocial debilitation associated with nail dystrophy. Unfortunately, no treatment presently in use is capable of curing psoriatic nails. Although numerous attempts and treatment modalities presently exist in the prior art, there is no specific consistently effective treatment for nail psoriasis.
Many modalities have been used, including topical, intralesional, and systemic modalities, radiation therapy, etc. However, most of these prior art treatment modalities had substantial risks and complications, including systemic
toxicity, post-radiation complications, atrophy of the surrounding skin, pain, etc. In addition, nail lacquers have been proposed in various prior art formulations for application to the nail for treating psoriasis, as well as many other nail disorders. However, these prior art nail lacquers have also proven to be ineffective in resolving the nail diseases for which they were intended. As a result, a long-felt need has continued to exist for a safe, effective treatment system for nails and nail diseases, with no satisfactory proposal being found until the present invention that will be easy to use, safe, and cost efficient.
Therefore, it is a principal object of the present invention to provide a treatment system for humans which is capable of being conveniently and easily employed on any desired surface of a human, including the nail surface and skin surface, providing a quick drying film, which incorporates desired therapeutic agents for treating various medical problems.
Another object of the present invention is to provide a highly effective treatment system having the characteristics featured detailed above which also employs a heat gradient to further enhance the delivery of the therapeutic agents.
Another object of the present invention is to provide a highly effective treatment system having the characteristics featured detailed above which is capable of being easily and effectively employed for treating a wide variety of medical conditions.
Another object of the present invention is to provide a highly effective treatment system having the characteristics featured detailed above which also incorporates a holding and supporting member constructed or cooperation with the film forming composition and the heat producing member to assure ease of application and use.
Other and more specific objects will in part be obvious and will in part appear hereinafter.
DETAILED DESCRIPTION
By employing in the present invention, all of the difficulties and drawbacks found in prior art compositions, systems, methods and procedures are eliminated, and a local, easily employed, convenient, consumer-oriented treatment system is achieved for treating nails and/or skin surfaces having a wide variety of medical problems. In the present invention, a treatment system is attained which comprises a film forming composition incorporating one or more therapeutic substances for application to nails and/or skin surfaces which can be employed independently or, if desired, in combination with an easily employed holding or support member for delivering heat directly to the application site.
The treatment system of the present invention possesses broad applicability for a wide range of medical conditions. In particular, the numerous diseases, disorders, and medical problems detailed above are all capable of being treated using the present invention. In particular, diseases, disorders, and medical conditions including, but not limited to psoriasis, skin cancers, warts, leishmaniasis, mycobacteria, and granuloma annulare can be specifically treated or improved due to the efficacy of the present invention and, when employed, the efficacy of heat penetration in treating these disorders.
In this regard, it has been established that the application of heat slows, inhibits, or reverses metabolic processes, immunological processes, or biological conditions or processes which depend upon heat or are affected by heat. As a result, numerous medical conditions are effectively treated by employing the therapeutic or drug bearing film forming compositions detailed herein in combination with a heating source, in accordance with the embodiment of this invention which comprises the integrated treatment system.
It has also been found that the use of heat produces a positive, synergistic effect on the targeted, controlled delivery of predetermined amounts of drugs, and/or penetration enhancing agents. In this regard, the topical use of the drugs
and/or penetration enhancing agents for the treatment of the nail diseases, disorders, and medical conditions and/or skin and subcutaneous surfaces, as fully detailed above, are improved or effectively treated by the use of the present invention. Furthermore, the delivery of drugs and/or penetration enhancing agents to the nail, or through the nail to the underlying tissue, for the purpose of achieving a non-oral and/or non-parenteral, systemic, transdermal delivery is effective on its own and is further enhanced by the presence of a controlled heat gradient.
Generally, the treatment system of the present invention is detailed below in association with its application to nails and the underlying tissue associated with nails. However, the present invention has equal applicability to diseases, disorders, and medical problems found on skin surfaces which are unassociated with nails. Consequently, it is to be understood that the present invention and the disclosure provided herein is equally applicable to use on any skin surface. Consequently, the detailed use and application to the nails is provided for exemplary purposes only and, as a result, the present invention is intended to encompass application and use on both nails and skin surfaces.
One principal component of the present invention is a film forming composition which is specifically formulated for delivering one or more therapeutic substances to the site on which it is applied. While usable on any surface of the human body, the film forming position is particularly usable on nails for treating any desired nail disease.
In addition to comprising one or more therapeutic substances, the film forming composition of this invention also preferably comprises a film former, a plasticizer, and urea, all of which are in a volatile carrier. By referring to Table I, the formulation ranges for each ingredient are readily apparent. In this Table, both the overall usable ranges and preferred ranges are provided.
TABLE I
In forming the composition of the present invention, any desired film former may be employed. However, in the preferred composition, the film former comprises at least one selected from the group consisting of poly vinyl acetate, mixed polymers of vinyl acetate and acrylic acid, mixed polymers of (meth) acrylic acid and (meth) aery late esters, poly vinyl acetate, poly vinyl butyryl, poly vinyl alcohols, cellulose derivatives such as cellulose acetate phthalate, cellulose acetate butyrate, cellulose acetate propionate, cellulose nitrate, cellulose sulfate, ethylcellulose, and cellulose acetate. In this regard, one preferred film former is ammonio methacrylate copolymer (II) sold under the brand name "Eudragit RL-100" by Rohm Pharma GmbH, Weiterstadt, Germany.
In addition, any desired plasticizers may be employed. However, in the preferred composition, the plasticizer composition comprises as least one selected from the group consisting of triacetin, polyhydric alcohols such as propylene glycol and butylene glycol, castor oil, camphor and phthalates. In this regard, one preferred plasticizer comprises dibutyl phthalate, sold under the brand name "Eastman DBT Plasticizer" by Eastman Chemicals.
In formulating the compositions of the present invention, any suitable solvent or volatile carrier may be employed. However, it has been found that the solvent/volatile carrier preferably comprises one or more selected from the group consisting of alcohols (such as ethanol), ketones (such as acetone), ethers (such as
chloroform), aromatic hydrocarbons (such as toluene), esters (such as ethyl acetate), and water.
In selecting or formulating a combination of ingredients for the sol vent/ volatile carrier, it has been found that the preferred compound or compounds should act as a solvent for the carrier and at an evaporation rate which is slow enough to allow a complete application of the active ingredients to nail or skin surfaces, as well as being fast enough to prevent rub-off of the composition in the event the nail or skin surface comes into contact with another surface.
One preferred formulation for the therapeutic film forming composition is detailed in Table II. In forming this preferred composition, the film former namely Eudragit RL-100, is first dissolved in the acetone/ethanol/water carrier. After a clear solution is formed, the other ingredients are added and intermixed therein until completely dissolved. In addition, the desired therapeutic agents are also added and intermixed therewith to form the desired therapeutic film forming composition for application to the nails or skin.
TABLE II
In completing the therapeutic film forming composition of this invention, one or more therapeutic substances are incorporated into the compositions in sufficient quantity to provide the effect desired. In general, the therapeutic substance
employed comprises one or more selected from the group consisting of corticosteroids, chemotherapeutic agents, anesthetics, antihistamines, anti- bacterials, anti-parasitics, anti-viral agents, anti-oxidants, tar, anthralines, immunomodulators, keratolytics, and anti-neoplasties. Although a wide variety of chemical products come within the scope of these medications, the following list provides typical compositions that are effectively employed as a part of the treatment system of the present invention. However, this listing is provided for exemplary purposes only, and is not intended to limit the present invention thereto. In this regard, corticosteroids may comprise one or more selected from the group consisting of hydrocortisone, triamcinolone, betamethasone, and any other steroids commonly used in topical applications to the skin; chemothera-peutic agents may comprise one or more selected from the group consisting of 5FU, Bleomycin, methotrexate, cytotoxic agents; anesthetics may comprise one or more selected from the group consisting of lidocaine, prilocaine, and pramoxine, antihistamines may comprise one or more selected from the group consisting of diphenhydramine and its salts; or doxepin, anti-bacterials may comprise one or more selected from the group consisting of gentamicin, tetracycline, erythromycin, and clindamycin; anoxicillin, anti-parasitics may comprise one or more selected from the group consisting of metronidazole, permethrin, and crotamiton; anti-virals may comprise one or more selected from the group consisting of acyclovir; antioxidants may comprise one or more selected from the group consisting of ascorbic acid and tocopherol; immunomodulators may comprise one or more selected from the group consisting of imiquimod and beta glucan; keratolytics may comprise one or more selected from the group consisting of salicylic acid; and anti-neoplasties may comprise one or more selected from the group consisting of cytotoxic agents and immunomodulators. Furthermore, as detailed herein, it has also been discovered that the use of a heat gradient, as provided by one of the alternate embodiments of the present invention, is effective in causing enhancing agents to be more efficiently employed. In this regard, as is fully detailed below, enhancing agents which particularly benefit
from the use of this embodiment of the present invention comprise one or more selected from the group consisting of solvents, surfactants, ethers, esters, fatty acid glycerides, urea, oleates, liposomes, retinoids, and occlusive compounds.
As discussed above, the present invention comprises the use of a therapeutic film forming composition independently in one embodiment, and also comprises the use of a heat delivery member which is employed in combination with the therapeutic film forming composition. In the use of the present invention on a nail and/or skin surfaces, the therapeutic film forming composition is applied to the nail and/or skin surface. Once the film layer is established, the heat delivery member, when employing this embodiment, is placed over the nail to provide a continuous heat gradient directly to the affected nail and/or skin surface.
As stated above, the application of heat has been found to enhance the delivery and efficacy of many therapeutic substances. When employing this embodiment, heat delivery is preferably achieved by employing a heat delivery pad used in combination with a holding member. In the preferred construction, an exothermic pad or heat delivery patch is employed for the heat source. Exothermic pads or heat delivery patches have been previously developed and typically comprise a porous film or pad of woven or non-woven material incorporating chemicals which will react exothermically to generate heat in the presence of oxygen. Although any desired chemicals can be employed, exothermic pads or heat delivery patches typically contain moxa or a mixture of iron powder, activated charcoal, wood fibers, water and salt. Alternatively, a mixture of alkaline sulfides and iron carbide are employed with the chemicals stored in an inert, oxygen-free, chamber to prevent exposure to oxygen prior to use. In addition, the pores of the pad are of sufficient size to assure that the required air flow is achieved. If desired, any alternate heat producing pad, product, or construction can be employed.
Prior to use, the patch/pad is typically sealed within a pouch which is odorless or formed with an inert gas, such as nitrogen. As long as the patch/pad remains in the sealed container until use, no chemical reaction takes place.
However, once the pouch is open, the presence of the oxygen in the air causes the chemicals to react and the desired exothermic reaction is produced.
In this embodiment of the present invention, the exothermic pad or heat delivery patch is separately employed by having the user place the pad or patch on the desired site where heat treatment is being sought. If desired, the heat delivery patch or exothermic pad is separately secured to the desired site by adhesive means associated therewith.
Once the patch/pad is secured in the precisely desired location, the holding member of the treatment system of the present invention is affixed to the desired location, peripherally surrounding and securely maintaining the heating pad or exothermic patch in the desired location, assisting in regulating and controlling the heat level and air transmission to the exothermic pad or heat delivery patch. In this way, the desired, controlled heat delivery or heat gradient is realized, enabling a broad range of medical conditions to be effectively treated. In addition to providing controlled heat delivery for the direct treatment of certain medical conditions, the use of a heat gradient as provided by this embodiment of the fully integrated treatment system of the present invention is effective, improving and enhancing the penetration of the systemic and topical medications incorporated in the therapeutic film forming composition. As is evident from the foregoing, a wide variety of broadly diverse medical conditions are effectively and efficiently treated using the treatment system of the present invention. As detailed above, one embodiment of the treatment system of the present invention incorporates a heat delivery patch or exothermic pad in combination with a holding member which maintains the heat delivery patch or exothermic pad in a precisely desired location where the particular medical problem is manifested or where heat delivery or a heat gradient is desired. In addition, nail or skin penetration enhancing agents may be integrated into the treatment system of this invention for further enhancement of its efficacy.
One area in which the use of heat has been widely documented is in the treatment of warts. In this regard, heat treatment for warts is fully disclosed in Dvoretzkv. U.S. Patent 5,053,024. However, the use of heat in treating other skin disorders or medical conditions as well as the use of heat for assisting in the transmission and/or absorption of medicines and nail/skin penetration enhancing agents is generally unknown and represents an advance in this technological area, particularly in combination with a therapeutic film forming composition.
By employing this embodiment of the treatment system of the present invention, which comprises a therapeutic film forming composition in combination with a holding member and a heat delivery patch or exothermic pad, the temperature of the nail or skin is elevated and maintained between about 39° to 45 °C , for periods of time ranging between about 1 and 10 hours. In addition, by employing the present invention, the heat level to which the nail or skin is exposed is maintained in a small, controlled range, which represents the optimum heat exposure for treating the medical condition and delivering the precisely desired medicines. As a result, optimum performance and treatment is realized.
In accordance with the present invention, the support member is specifically designed for being quickly and easily mountable to a part of the body, such as a finger, in peripheral, surrounding engagement with the nail being treated, and remain in the precisely desired location in cooperating association with the film forming composition and the heat delivery patch or exothermic pad. Furthermore, the support member of the present invention is also specifically constructed from material particularly designed for cooperating with a heat delivery patch or exothermic pad to synergistically interact therewith for assuring that the precisely required temperature levels are maintained and optimum oxygen flow is realized for the precisely desired period of time.
The support member forming a component of the holding system of the present invention may be constructed in a variety of alternate configurations for providing the desired, quicky, easy, secure mounting thereof directly to any finger
or toe, or any other portion of the human anatomy where treatment is likely to be needed. In this regard, one embodiment of the holding system of the present invention comprises a continuous, substantially cylindrically shaped tube member. By employing a cylindrically shaped member, the holding system of the present invention is able to be easily mounted onto the hands or feet of the user, peripherally surrounding the nail to be treated, securely maintaining and cooperating with the pre-mounted exothermic pad or heat delivery patch in the precisely desired location.
One feature of the present invention is the material employed for forming the treatment system of this invention. In this regard, most woven or non-woven materials are capable of being employed for forming the holding member. However, it has been found that the preferred material comprises an elastomer in its entirety or formed therein, in order to provide flexibility in easily mounting and securing the holding system in place. In one preferred construction, the elastomer is integrally formed as a part of the material, such as a thermoplastic elastomer. In this regard, the preferred thermoplastic material comprises a foamed thermoplastic elastomer selected from the group consisting of polyurethane, polyolefins, polybutylenes, polyethylenes, polyesters, ethylene-propylene rubbers, polypropylenes, silicones, and vinyl based resins. By employing a foamed thermoplastic elastomer, a precisely desired combination of closed cells and open cells is obtained, with the ratio of closed cells to open cells being controlled within a preferred range. In this way, the heat retention and/or insulation capabilities of the material are precisely controlled as well as the ability of the material to transmit oxygen from the surrounding, ambient air directly to the location of the heat delivery patch or exothermic pad.
In accordance with the embodiment of present invention wherein heat delivery is employed, the temperature delivered directly to the nail or skin surface by the exothermic pad or heat delivery patch is precisely controlled in a narrow range, for a predetermined length of time, due to the insulation provided by the
holding system. In addition, oxygen is circulated continuously through the holding system to provide proper operation of the exothermic pad/patch as well as provide air circulation to the surface of the nail or skin being treated.
It will must be seen that the object set forth above, among those made apparent from the preceding description, are efficiently obtained and, since certain changes may be made in carrying out the above process, in the described product, and in the constructions set forth without departing from the scope of the invention, it is intended that all matter contained in the above description shall be interpreted as illustrative and not in a limiting sense. It is also to be understood that the following claims are intended to cover all of the generic and specific features of the invention herein described, and all statements of the scope of the invention which, as a matter of language, might be said to fall therebetween.
Particularly, it is to be understood that in said claims, ingredients or compounds recited in the singular are intended to include compatible mixtures of such ingredients whenever the sense permits.
Having described our invention, what we claim as new and desired to secure by Letters Patent is:
Claims
1. A film forming treatment composition for localized, topical application on humans for providing transdermal delivery of a desired therapeutic agent, said composition comprising A. between about 0.5% and 25% by weight/ volume based upon the weight/volume of the entire composition of film former;
B. between about 0.5% and 25% by weight/ volume based upon the weight/volume of the entire composition of a plasticizer;
C. between about 0.5% and 20% by weight/ volume based upon the weight/volume of the entire composition of urea;
D. between about 40% and 90% by weight/volume based upon the weight/ volume of the entire composition of a solvent/ volatile carrier; and
E. an effective amount of at least one therapeutic substance; whereby a film forming treatment composition is attained which is capable of being applied to any desired area of an individual for providing localized, topical treatment for particular, specific diseases.
2. The treatment composition defined in Claim 1, wherein said film former is further defined as comprising one selected from the group consisting of polyvinyl acetate, mixed polymers of vinyl acetate and acrylic acid, mixed polymers of acrylic acids and aery late esters, polyvinyl acetate, polyvinyl butyryl, polyvinyl alcohols, cellulose derivatives, cellulose acetate phthalate, cellulose acetate butyrate, cellulose acetate propionate, cellulose nitrate, cellulose sulfate, ethylcellulose, and cellulose acetate.
3. The treatment composition defined in Claim 1, wherein said film former is further defined as comprising ammonio methacrylate copolymer.
4. The treatment composition defined in Claim 1, wherein said plasticizer is further defined as comprising at least one selected from the group consisting of triacetin, polyhydric alcohols, propylene glycol, butylene glycol, castor oil, camphor and phthalates.
5. The treatment composition defined in Claim 4, wherein said plasticizer is further defined as comprising dibutyl phthalate.
6. The treatment composition defined in Claim 1, wherein said solvent/volatile carrier comprises at least one selected from the group consisting of alcohols, ethanols, ketones, acetones ethers, chloroforms, aromatic hydrocarbons, toluenes, esters, ethyl acetate, and water.
7. The treatment composition defined in Claim 1, wherein said solvent/volatile carrier comprises an evaporation rate which allows the complete application of the active ingredients of the composition to the skin surface while also preventing the composition from being rubbed off when the treated surface comes into contact with another surface.
8. The treatment composition defined in Claim 7, wherein the solvent/ volatile carrier is further defined as comprising 50% by weight/volume of acetone intermixed with 50% by weight/volume of ethanol.
9. The treatment composition defined in Claim 1, wherein the therapeutic agent comprises one or more selected from the group consisting of corticosteroids, chemotherapeutic agents, anesthetics, antihistamines, anti-bacterials, anti-parasitics, anti-viral agents, anti-oxidants, tar, anthralines, immunomodulators, keratolytics, and anti-neoplasties.
10. The treatment composition defined in Claim 9, wherein the therapeutic agent is further defined as comprising one or more selected from the group consisting of hydrocortisone, triamcinolone, betamethasone, 5FU, bleomycin, methotrexate, cytotoxic agents, lidocaine, prilocaine, diphenhydramine and its salts, doxepin, gentamicin, tetracycline, erythromycin, clindamycin, metronidazole, permethrin, crotamiton, acyclovir, ascorbic acid, tocopherol, imiquimod, beta glucan, salicylic acid, cytotoxic agents and immunomodulators.
11. The treatment composition defined in Claim 1 , wherein said composition further comprises an enhancing agent for assisting in the delivery of the therapeutic substance.
12. The treatment composition defined in Claim 11, wherein said composition is further defined as comprising heat delivery means constructed for cooperative, overlying engagement therewith for providing a heat gradient to the use and delivery of said treatment composition.
13. The treatment composition defined in Claim 12, wherein said enhancing agent comprises one or more selected from the group consisting of solvents, surfactants, ethers, esters, fatty acid glycerides, urea, oleates, liposomes, retinoids, and occlusive compounds.
14. A treatment system for providing the effective transdermal delivery of therapeutic agents to humans for treating a wide variety of medical conditions, said system comprising:
1. A film forming composition comprising: 1. between about 0.5% and 25% by weight/ volume based upon the weight/volume of the entire composition of film former;
2. between about 0.5% and 25% by weight/ volume based upon the weight/volume of the entire composition of a plasticizer;
3. between about 0.5% and 20% by weight/ volume based upon the weight/volume of the entire composition of urea;
4. between about 40% and 90% by weight/ volume based upon the weight/volume of the entire composition of a solvent/volatile carrier; and
5. an effective amount of at least one therapeutic substance; B. a heat generating pad incorporating heat producing means contained therein and constructed for delivering the desired level of heat upon activation; and C. a holding and supporting member constructed for
1. cooperating with the heat generating pad for enabling the application of heat directly to a desired application site of the film forming composition; and
2. being securely retained on a portion of the human body in overlying engagement with the heat delivery patch/pad and the film forming composition; whereby a treatment system is realized which is capable of being secured to any desired part of the human body to provide therapeutic agents and heat to any desired site in a precisely controlled manner.
15. The treatment system defined in Claim 14 wherein the holding member is constructed for mounting securement to one body part selected from the group consisting of fingers, arms, elbows, toes, feet, legs, wrists, ankles, and the upper torso.
16. The treatment system defined in Claim 14, wherein said holding and supporting member comprises an elongated, substantially planar construction incorporating fastening means for securing said member in any desired location.
17. The treatment system defined in Claim 16, wherein said fastening means is defined as comprising one selected from the group consisting of adhesives and hook and loop fasteners.
18. The treatment system defined in Claim 14, wherein said holding and support member is further defined as being formed from thermoplastic elastomeric materials.
19. The treatment system defined in Claim 18, wherein said thermoplastic elastomeric material is defined as comprising one selected from the group consisting of polyurethanes, polyolefins, polybutylenes, polyethylenes, polyesters, ethylene- propylene rubbers, polypropylenes, silicones, and vinyl-based resins.
20. The treatment system defined in Claim 17, wherein said fastening means are defined as comprising at least two cooperating, interlocking members affixed to opposed surfaces of the holding and supporting member and positioned for mating, cooperating, interengagement with each other for securely maintaining the holding and supporting member in any desired position or location on an individual.
21. The treatment system defined in Claim 20, wherein said pair of cooperating, interlocking members are further defined as comprising hook and loop fastening means with the first of said pair of interlocking members being mounted on a first surface of the holding and supporting member in spaced, cooperating relationship with the heat generating pad mounted thereto, and a second interlocking hook and loop fastening member being securely affixed to substantially the entire opposed surface of the holding and supporting member whereby cooperating, locked mounted interengagement of said first and second interlocking members is quickly and easily attained at virtually any desired location or position.
22. The treatment system defined in Claim 17, wherein said mounting means is further defined as comprising an adhesive layer affixed to one surface of the holding and supporting member in association with the heat generating pad for enabling the fastening means to securely affix the holding and supporting member and heat generating pad to any desired position or location on the skin of the individual.
23. The treatment system defined in Claim 17, wherein said heat generating pad is further defined as being activated by exposure to oxygen and said treatment system is further defined as being packaged in an oxygen free, peripherally surrounding releasable container, thereby enabling a single heat generating pad to be reusably employed for short time periods by storing the delivery system in the releasable container when not in use.
24. The treatment system defined in Claim 14, wherein said film former is further defined as comprising one selected from the group consisting of polyvinyl acetate, mixed polymers of vinyl acetate and acrylic acid, mixed polymers of acrylic acids and aery late esters, polyvinyl acetate, polyvinyl butyryl, polyvinyl alcohols, cellulose derivatives, cellulose acetate phthalate, cellulose acetate butyrate, cellulose acetate propionate, cellulose nitrate, cellulose sulfate, ethylcellulose, and cellulose acetate.
25. The treatment system defined in Claim 24, wherein said plasticizer is further defined as comprising at least one selected from the group consisting of triacetin, polyhydric alcohols, propylene glycol, butylene glycol, castor oil, camphor and phthalates.
26. The treatment system defined in Claim 25, wherein said solvent/ volatile carrier comprises at least one selected from the group consisting of alcohols, ethanols, ketones, acetones ethers, chloroforms, aromatic hydrocarbons, toluenes, esters, ethyl acetate, and water.
27. The treatment system defined in Claim 26, wherein the therapeutic agent comprises one or more selected from the group consisting of corti-costeroids, chemotherapeutic agents, anesthetics, antihistamines, anti-infectives, anti-fungals, anti-bacterials, anti-parasitics, anti-viral agents, anti-oxidants, tar, anthralines, immunomodulators, keratolytics, and anti-neoplasties
28. The treatment system defined in Claim 14, wherein said film forming composition further comprises an enhancing agent for assisting in the delivery of the therapeutic substance.
29. The treatment system defined in Claim 28, wherein said enhancing agent comprises one or more selected from the group consisting of solvents, surfactants, ethers, esters, fatty acid glycerides, urea, oleates, liposomes, retinoids, and occlusive compounds.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26043001P | 2001-01-09 | 2001-01-09 | |
| US260430P | 2001-01-09 | ||
| PCT/US2002/000282 WO2002055023A2 (en) | 2001-01-09 | 2002-01-07 | Therapeutic film forming composition and treatment system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1357873A2 true EP1357873A2 (en) | 2003-11-05 |
| EP1357873A4 EP1357873A4 (en) | 2009-09-09 |
Family
ID=22989129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP02717290A Withdrawn EP1357873A4 (en) | 2001-01-09 | 2002-01-07 | Therapeutic film forming composition and treatment system therefor |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1357873A4 (en) |
| JP (1) | JP2004520337A (en) |
| KR (1) | KR20030072592A (en) |
| CN (1) | CN1281287C (en) |
| AU (1) | AU2002248308B2 (en) |
| BR (1) | BR0206307A (en) |
| CA (1) | CA2431236A1 (en) |
| HU (1) | HUP0501023A3 (en) |
| IL (1) | IL156458A0 (en) |
| NO (1) | NO20033123L (en) |
| NZ (1) | NZ526806A (en) |
| PL (1) | PL362920A1 (en) |
| WO (1) | WO2002055023A2 (en) |
| ZA (1) | ZA200305125B (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8907153B2 (en) | 2004-06-07 | 2014-12-09 | Nuvo Research Inc. | Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same |
| US8741332B2 (en) | 2004-06-07 | 2014-06-03 | Nuvo Research Inc. | Compositions and methods for dermally treating neuropathic pain |
| US8741333B2 (en) | 2004-06-07 | 2014-06-03 | Nuvo Research Inc. | Compositions and methods for treating dermatitis or psoriasis |
| JP4863437B2 (en) * | 2005-07-07 | 2012-01-25 | 有限会社日本健康科学研究センター | Bath film formulation |
| EP1959929A4 (en) * | 2005-12-14 | 2012-08-15 | Zars Pharma Inc | Compositions and methods for treating dermatological conditions |
| JP5137175B2 (en) * | 2006-10-24 | 2013-02-06 | 有限会社日本健康科学研究センター | Film guard formulation |
| EP1958613A1 (en) * | 2007-02-15 | 2008-08-20 | Polichem S.A. | Dermal film-forming liquid formulations for drug release to skin |
| FR2937250B1 (en) * | 2008-10-21 | 2013-05-10 | Fabre Pierre Dermo Cosmetique | UREA-BASED FILMOGENOUS SOLUTION FOR THE TREATMENT OF NAIL PSORASIS |
| US8771656B2 (en) * | 2011-12-14 | 2014-07-08 | Avon Products, Inc | Long-lasting easy wash-off cosmetic compositions |
| KR20150038212A (en) * | 2012-07-23 | 2015-04-08 | 다우 글로벌 테크놀로지스 엘엘씨 | Film composition for hard capsule shells |
| EP2705847B1 (en) * | 2012-09-05 | 2014-07-02 | PSoriasis+Creams Sweden AB | Composition for treating psoriasis |
| JP6596432B2 (en) * | 2014-01-20 | 2019-10-23 | メリアル インコーポレイテッド | Topical delivery formulation |
| CN104771781A (en) * | 2014-08-20 | 2015-07-15 | 江阴市柏御天谷生物医药有限公司 | Liquid wound protection film and preparation method thereof |
| CN105999393A (en) * | 2016-07-15 | 2016-10-12 | 蓝佳堂生物医药（福建）有限公司 | Liquid band-aid and preparation method thereof |
| CN107320766A (en) * | 2016-12-08 | 2017-11-07 | 沈阳圣劳伦斯医疗器械有限公司 | A kind of composition for skin superficial protecting wound surface |
| CN108785739A (en) * | 2018-08-13 | 2018-11-13 | 中国人民解放军南京军区福州总医院 | A kind of full-service fluid adhesive bandage and preparation method thereof |
| CN110859989B (en) * | 2019-10-25 | 2021-06-22 | 天津冠勤医药科技有限公司 | Liquid band-aid and preparation method thereof |
| CN111166932B (en) * | 2020-02-29 | 2021-01-26 | 海南妙音春制药有限公司 | Liquid wound spray dressing and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2188844A (en) * | 1986-04-11 | 1987-10-14 | Roehm Pharma Gmbh | Pharmaceutical composition for the treatment of psoriasis |
| EP0913154A1 (en) * | 1997-08-21 | 1999-05-06 | Hoechst Marion Roussel Deutschland GmbH | Antipsoriatic nail lacquer |
| US5918590A (en) * | 1995-06-29 | 1999-07-06 | The Procter & Gamble Company | Heat cells |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4212105A1 (en) * | 1992-04-10 | 1993-10-14 | Roehm Pharma Gmbh | Nail polish for the treatment of onychomycoses |
| US5534021A (en) * | 1994-09-01 | 1996-07-09 | Dvoretzky; Israel | Heating pad for providing heat therapy |
-
2002
- 2002-01-07 NZ NZ526806A patent/NZ526806A/en unknown
- 2002-01-07 CN CNB028035100A patent/CN1281287C/en not_active Expired - Fee Related
- 2002-01-07 PL PL02362920A patent/PL362920A1/en unknown
- 2002-01-07 CA CA002431236A patent/CA2431236A1/en not_active Abandoned
- 2002-01-07 EP EP02717290A patent/EP1357873A4/en not_active Withdrawn
- 2002-01-07 IL IL15645802A patent/IL156458A0/en not_active IP Right Cessation
- 2002-01-07 KR KR10-2003-7009178A patent/KR20030072592A/en not_active Application Discontinuation
- 2002-01-07 HU HU0501023A patent/HUP0501023A3/en unknown
- 2002-01-07 WO PCT/US2002/000282 patent/WO2002055023A2/en active Application Filing
- 2002-01-07 JP JP2002555760A patent/JP2004520337A/en active Pending
- 2002-01-07 AU AU2002248308A patent/AU2002248308B2/en not_active Ceased
- 2002-01-07 BR BR0206307-7A patent/BR0206307A/en not_active IP Right Cessation
-
2003
- 2003-07-01 ZA ZA200305125A patent/ZA200305125B/en unknown
- 2003-07-08 NO NO20033123A patent/NO20033123L/en not_active Application Discontinuation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2188844A (en) * | 1986-04-11 | 1987-10-14 | Roehm Pharma Gmbh | Pharmaceutical composition for the treatment of psoriasis |
| US5918590A (en) * | 1995-06-29 | 1999-07-06 | The Procter & Gamble Company | Heat cells |
| EP0913154A1 (en) * | 1997-08-21 | 1999-05-06 | Hoechst Marion Roussel Deutschland GmbH | Antipsoriatic nail lacquer |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO02055023A2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1281287C (en) | 2006-10-25 |
| HUP0501023A3 (en) | 2008-04-28 |
| NO20033123L (en) | 2003-09-03 |
| CN1514706A (en) | 2004-07-21 |
| ZA200305125B (en) | 2004-10-01 |
| AU2002248308B2 (en) | 2006-12-07 |
| KR20030072592A (en) | 2003-09-15 |
| WO2002055023A3 (en) | 2002-11-07 |
| NO20033123D0 (en) | 2003-07-08 |
| JP2004520337A (en) | 2004-07-08 |
| CA2431236A1 (en) | 2002-07-18 |
| EP1357873A4 (en) | 2009-09-09 |
| HUP0501023A2 (en) | 2007-02-28 |
| PL362920A1 (en) | 2004-11-02 |
| IL156458A0 (en) | 2004-01-04 |
| BR0206307A (en) | 2004-07-20 |
| NZ526806A (en) | 2006-03-31 |
| WO2002055023A2 (en) | 2002-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002248308B2 (en) | Therapeutic film forming composition and treatment system | |
| US20080102108A1 (en) | Therapeutic film forming composition and treatment system therefor | |
| AU2002248308A1 (en) | Therapeutic film forming composition and treatment system | |
| US6337076B1 (en) | Method and composition for the treatment of scars | |
| AU2006326018B2 (en) | Compositions and methods for dermally treating pain | |
| US7959904B2 (en) | Delivery of medicaments to the nail | |
| SI20360A (en) | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate | |
| AU778280B2 (en) | Multi-purpose drug and heat therapy treatment system | |
| US20070059349A1 (en) | Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate | |
| JP2008515911A (en) | Organogel preparation for treatment | |
| MX2007003995A (en) | Organo-gel formulations for therapeutic applications. | |
| JP2009519958A (en) | Fluxable compositions and methods for skin delivery of drugs | |
| JPH06503576A (en) | Methods and systems for transdermally administering drugs using sorbitan esters as skin penetration enhancers | |
| WO2009017767A2 (en) | Compositions and methods for dermally treating neuropathy with minoxidil | |
| JPS60150755A (en) | Wound treating article made of synthetic resin and its treatment and use | |
| CN101494976B (en) | Compositions and methods for dermally treating pain | |
| WO2012064766A2 (en) | Sheet and liquid combination systems for dermal drug delivery | |
| TW200902090A (en) | Transdermal administration device for bisoprolol | |
| JPH02215710A (en) | Local application of drug contained in binder | |
| Al-Jarsha et al. | A review on film forming drug delivery systems | |
| JPH01299228A (en) | Filmy percutaneous absorption preparation | |
| GR20190100103A (en) | Paste for the prevention and therapy of bedsores and decubitus ulcers - production method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20030628 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20090807 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 9/70 20060101ALI20090803BHEP Ipc: A61F 13/00 20060101AFI20030709BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
| 18W | Application withdrawn |
Effective date: 20090902 |